Anterios is a privately held, clinical-stage biopharmaceutical company
that is developing next-generation botulinum-based prescription products for medical dermatology and aesthetic medicine.

Anterios has developed NDSTM, a proprietary platform technology that enables local, targeted delivery of botulinum toxin and other macromolecules across the skin without needles or other invasive treatments that can be destructive to the skin. NDS also enables the formulation of macromolecules as ready-to-use liquid injectable products.

In the future, Anterios plans to develop additional dermatology products to topically deliver active ingredients other than botulinum, as well as formulate additional injectable products that require deeper delivery.